Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 11,699 Shares of Stock

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 11,699 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the sale, the executive vice president owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. This represents a 9.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Merck & Co., Inc. Stock Performance

NYSE MRK traded up $2.68 during trading on Wednesday, reaching $133.10. The company’s stock had a trading volume of 9,894,503 shares, compared to its average volume of 10,707,019. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market cap of $328.38 billion, a price-to-earnings ratio of 106.48, a P/E/G ratio of 5.66 and a beta of 0.19. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The business’s fifty day moving average price is $124.58 and its 200-day moving average price is $119.47.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Daiwa upgraded Merck to “outperform” and set a $143 price target, implying additional upside from recent trading levels. Finviz analyst upgrade
• Positive Sentiment: Argus raised its price target to $145 and reiterated a “buy” rating, adding to the positive analyst momentum around MRK. Benzinga analyst action
• Positive Sentiment: Erste Group increased its FY2026 earnings estimate to $2.75 per share from $2.70, bringing its forecast close to the $2.76 consensus estimate. MarketBeat earnings estimate
• Positive Sentiment: The FDA and EMA accepted applications to expand ENFLONSIA for RSV prevention in additional high-risk young children. The regulatory milestone could broaden Merck’s growth opportunities beyond oncology and help diversify its portfolio as Keytruda faces future patent challenges. Merck ENFLONSIA regulatory news
• Positive Sentiment: Merck’s latest results included $16.61 billion in revenue, above analyst expectations, with oncology and animal health contributing to performance. The company also continues to attract institutional ownership, which exceeds 76%. Merck earnings call transcript

Analyst Upgrades and Downgrades

MRK has been the subject of several analyst reports. Guggenheim upped their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Bank of America lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. boosted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Argus raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $135.50.

Institutional Trading of Merck & Co., Inc.

Hedge funds have recently modified their holdings of the business. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the fourth quarter worth $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Graney & King LLC grew its stake in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.